Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

12,012,000 7,440,000

Capital lease obligation, less current

portion 16,000 22,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock -- $.001 par value;

authorized 5,000,000 shares; non-voting;

nil shares outstanding - -

Common stock -- $.001 par value;

authorized 325,000,000 shares;

outstanding -- 226,210,617 and 226,210,617,

respectively 226,000 226,000

Additional paid-in capital 246,476,000 246,205,000

Accumulated deficit (235,922,000) (230,836,000)

Total stockholders' equity 10,780,000 15,595,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $22,808,000 $23,057,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED

July 31, 2008 July 31, 2007

Unaudited Unaudited

REVENUES:

Contract manufacturing revenue $1,193,000 $1,621,000

Government contract revenue 324,000 -

License revenue - 4,000

Total revenues 1,517,000 1,625,000

COSTS AND EXPENSES:

Cost of contract manufacturing 903,000 1,181,000

Research and development 4,068,000 3,624,000

Selling, general and administrative 1,706,000 1,708,000

Total costs and expenses 6,677,000 6,513,000

LOSS FROM OPERATIONS (5,160,000) (4,888,000)

OTHE
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... August 26, 2014 New research ... wearable technology, and inspiration for the International Year ... year’s brighter, busier SPIE Optics + Photonics ... More than 4,400 international scientists, engineers, researchers, developers, ... exhibition, and industry sessions sponsored by SPIE, ...
(Date:8/26/2014)... team of engineers from Singapore has successfully piloted ... for satellite communications. , With the weight of ... constructing a lightweight, low power-consuming, wireless communication system ... has always been a challenge for system designers. ... Centre of Nanyang Technological University in Singapore launched ...
(Date:8/26/2014)... Aug. 26, 2014 An analysis by Replikins, ... all Dengue virus strains in Pubmed, has revealed extensive ... 1944. This conservation and sharing of specific Replikin gene ... Blocker-Vaccine™ candidate, as it did for the H5N1 influenza ... which have been found to be effective (1,2). ...
(Date:8/26/2014)... , Aug. 26, 2014 Technology Applications ... symbol (NUUU) has two (2) wholly- owned subsidiaries, ... subsidiaries harness scientifically advanced technology to provide advanced ... NUUU,s Renuell Int,l, Inc. is launching its ... care products that is made possible because of ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ZigBee in the Sky 2Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2
... the, prior year,s third quarter - Earnings per share of $0.28, ... cash flow of $23 million, (Year-to-date operating cash flow of $62 million) ... ... Biosciences,Corporation (Nasdaq: MATK ) today announced its financial results for the,third ...
... The Hamner Institutes and The University of North Carolina-Chapel ... Research Partnership in Drug Safety Sciences, RESEARCH TRIANGLE ... Sciences and the University of North Carolina at,Chapel Hill ... Safety,Sciences that will be led by Dr. Paul Watkins, ...
... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, today announced that ... common stock which will begin trading under the ... common stock will no longer trade,under the symbol ...
Cached Biology Technology:Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3
(Date:8/27/2014)... A growing number of studies have shown ... the pathogenesis of Parkinson,s disease. Previous studies ... Medical University in China have shown that ... injury, reduced divalent metal transporter 1 expression, ... substantia nigra of rotenone-induced Parkinson,s disease rats. ...
(Date:8/27/2014)... Happy Camp Complex of fires had consumed 24,939 acres ... consumed 35,530 as of eight hours ago. , ... Ranger District of the Klamath National Forest when a ... All but three of those fires are now 100 ... fires and their size at containment: Delta, 150 acres; ...
(Date:8/27/2014)... Carolina State University have found that century-old museum specimens hold ... insect pest that can weaken and kill trees and ... scale insect populations increase on oak and maple trees in ... may also increase with global warming," says Dr. Elsa Youngsteadt, ... a paper on the work. , "More scale insects would ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... and microorganisms, Systems Biology is regarded as the next ... allow biologists to spell all the letters in the ... way of deciphering this complex code. Pharma- and biotechnology ... tools for use in drug discovery and development., Systems ...
... cells, high school students and teachers sounds like a witches brew ... Instead, these are the components that ... curriculum being developed by researchers at Washington University in St. Louis ... Lars Angenent, Ph.D., assistant ...
... Commonwealth University Massey Cancer Center research team has received ... National Cancer Institute to improve the activity of a ... in the treatment of leukemia and other blood malignancies. ... associate director for translational research and co-leader of the ...
Cached Biology News:World class in Systems Biology is the aim 2World class in Systems Biology is the aim 3World class in Systems Biology is the aim 4Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3NCI renewal grant to develop new cancer therapies 2
...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: